AGENDA

I. Call to order in accordance with New Jersey Open Public Meeting Act

II. Roll Call

III. Review of draft meeting summary for April 19, 2017 meeting

IV. Secretary’s report

V. Old Business
   A. Smoking cessation therapy denials report
   B. Proposed protocol for safe and efficient use of eteplirsen (Exondys 51®)

VI. New Business
   A. Proposed protocol for safe and efficient use of deflazacort (Emflaza®)
   B. Proposed protocol for safe and efficient use of nusinersen (Spinraza®)
   C. Updated protocol for sofosbuvir (Sovaldi®) – include children and adolescents
   D. Updated protocol for sofosbuvir/ledipasvir (Harvoni®) - include children and adolescents

VII. Informational Highlights/Reports
   2. Summary of DURB Action Items
   3. (a) DHS, DHSS and MCO Programs Top Drugs Report (by amount paid and by category)
      (b) Physician-administered drugs by amount paid/category
   4. Medication information:
      (a) Desperate families driven to black market insulin
      (b) “Superbug” fungus new menace in US hospitals, mostly NY, NJ
      (c) Death from infections may be masking opioid claims
      (d) Opioid epidemic may be underestimated, CDC report says
      (e) FDA: Boxed warning for canagliflozin on amputation risk
      (f) Why are EpiPens so expensive?